COVID-19: Our Message & News Stories

EXPANDING OUR GLOBAL SERVICE OFFERINGS

AGC Biologics has acquired Molecular Medicine S.p.A. (“MolMed”), the leading-edge cell & gene therapy company in Milan, Italy. MolMed is a biotechnology company focused on research, development, production and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases.

See our Press Release

home-italy-facilities-v2

Right. On Time.

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), providing world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.

Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast track projects for orphan drugs and rare diseases.

 

Learn More

Capabilities Spotlight

Plasmid A2_final URL

Learn more


AGC BIOLOGICS CAN DEVELOP, MANUFACTURE AND DELIVER
WHAT YOU NEED, WHEREVER YOU ARE IN THE
WORLD  —  RIGHT WHEN YOU NEED IT.

To view the AGC Biologics Video Overview with Facility Tours CLICK HERE

RAPIDLY EXPANDING OUR CUSTOMER PORTFOLIO

AGC Biologics has purchased a state-of-the-art commercial manufacturing facility in Boulder, Colorado, U.S.A., which will provide AGC Biologics with additional capacity and significantly larger production scale. We expect to begin full-scale operations and manufacturing by April 2021 and are currently staffing several new positions.

Read Our Press Release

View Job Postings

boulder-facility-home